Defence Therapeutics Announces Closing of Private Placement of Units for Gross Proceeds of $9,595,000
MWN-AI** Summary
Defence Therapeutics Inc. (CSE: DTC) has successfully closed a private placement, raising gross proceeds of $9,595,000 through the issuance of 17,445,455 units. Each unit, priced at $0.55, consists of one common share and one warrant, which allows holders to purchase additional shares at $0.65 for two years from issuance. The financing received notable participation from two institutional investors who had previously entered into a binding term sheet for a $6 million investment. As part of this agreement, the investors will also receive an additional corporate finance fee in the form of 654,546 units and a non-refundable deposit of 118,182 units.
The funds raised during this private placement will be allocated towards advancing Defence Therapeutics' Antibody Drug Conjugate (ADC) and Radiopharmaceutical programs, developing strategic partnerships, and covering general working capital needs. Importantly, the warrants come with an equity blocker provision to ensure that no investor can exceed a 9.99% ownership stake in the company's shares.
Defence Therapeutics is focused on enhancing cancer treatments through its Accum® precision drug delivery platform, aiming to improve the efficacy of ADCs while minimizing side effects. The company emphasizes collaboration with pharmaceutical and biotech partners to expedite the development of transformative therapies.
This private placement adheres to Canadian securities regulations and is not registered under U.S. securities laws, meaning the units cannot be offered or sold in the United States unless specific legal requirements are met. Additionally, all securities from this offering will face resale restrictions as per Canadian law. The transaction concluded on March 6, 2026, marking a significant step in Defence Therapeutics' growth strategy.
MWN-AI** Analysis
Defence Therapeutics Inc. (CSE: DTC) has recently completed a private placement generating net proceeds of approximately $9.6 million, primarily aimed at advancing its innovative anticancer therapies, particularly the company's Antibody Drug Conjugate (ADC) and Radiopharmaceutical programs. This is an enticing opportunity for investors, considering the potential market for novel cancer treatments is on a robust upward trajectory.
The completed private placement, issuing 17,445,455 units at $0.55 per unit, reflects confidence from institutional investors in Defence's therapeutic pipeline. With each unit comprised of a common share and a warrant exercisable at $0.65 over the next 24 months, the terms present an added incentive for potential investment growth. The equity blocker provision restricting warrant exercise is notable, yet it signals a focus on maintaining a healthy balance of ownership among investors.
Defence is strategically poised to leverage this funding towards its ADC platform, which could transform cancer treatment by maximizing the efficacy of existing therapies while mitigating side effects. As advancements in biopharmaceutical technologies gain momentum, companies like Defence that are innovating within this space could benefit significantly from favorable regulatory environments and increasing market demand.
Investors should consider the inherent risks in biotech investments, including regulatory challenges and market needs, yet the potential returns can be substantial given the transformative nature of oncology treatments. Therefore, maintaining a watchful eye on Defence Therapeutics as they continue to evolve their operational strategy and collaborate with industry partners could prove beneficial.
In conclusion, investors should assess the risk-reward profile of Defence Therapeutics, especially given their innovative technology and the positive reception from institutional investors. As the company progresses, market participants may find opportunities for substantial returns, making Defence an interesting prospect for those focused on the burgeoning biotech field.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Montreal, Quebec--(Newsfile Corp. - March 9, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the closing of a private placement (the "Private Placement") of 17,445,455 units (the "Units") at a price of $0.55 per Unit, for aggregate gross proceeds to Defence of $9,595,000.25. Each Unit is comprised of one common share (each, a "Share") and one common share purchase warrant ("Warrants"). Each Warrant entitles its holder to acquire an additional common share of the Company at a price of $0.65 per share for 24 months following the date of issuance.
As previously announced, the Company executed a binding term sheet (the "Term Sheet") with two arm's length institutional investors (collectively, the "Investors") in connection with the Private Placement for aggregate gross proceeds of $6,000,000, pursuant to the terms and conditions of a sharing agreement (the "Sharing Agreement") dated and executed as of March 6, 2026 (the "Closing Date"). For more information, please see the Company's press release dated February 27, 2026.
All 10,909,091 Warrants issued pursuant to the Term Sheet are exercisable at an exercise price of $0.65 per Share for a period of 24 months following the Closing Date. The Warrants include an equity blocker provision that prohibits the holder from exercising any portion of the Warrants if such exercise would result in the holder owning more than 9.99% of the Company's outstanding Shares. The Investors received a corporate finance fee of 654,546 Units and a non-refundable deposit of 118,182 Units at the Private Placement price in connection with the Sharing Agreement.
Defence intends to use the proceeds from the Private Placement to advance its Antibody Drug Conjugate ("ADC") and Radiopharmaceutical programs, to develop partnerships and for working capital purposes. No finder's fees were paid in connection with the Private Placement.
Pursuant to applicable Canadian securities laws and in accordance with the Exchange policies, all securities issued under this Private Placement are subject to applicable resale restrictions under applicable securities laws. The Private Placement closed on March 6, 2026.
The Units described herein have not been, and will not be, registered under the U.S. Securities Act or any state securities laws, and accordingly, may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities requirements or pursuant to exemptions there from. This press release does not constitute an offer to sell or a solicitation to buy any securities in any jurisdiction.
About Defence Therapeutics:
Defence Therapeutics is a publicly traded biotechnology company committed to making cancer treatment more effective and safer. Using its Accum® precision drug delivery platform, Defence is working to enhance the potency of ADCs and other complex biologics at lower doses, with the goal of reducing side effects and improving access to advanced therapies. By pursing cutting edge science, and collaborating with pharma and biotech partners, Defence strives to bring transformative therapies to patients who need them most. To learn more about Defence Therapeutics and explore partnering opportunities, please visit www.defencetherapeutics.com or contact info@defencetherapeutics.com.
For further information:
Defence Therapeutics
Sebastien Plouffe
CEO, Founder and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
Cautionary Statement Regarding "Forward-Looking" Information
This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/287702
FAQ**
How does Defence Therapeutics Inc. (CSE: DTC) plan to utilize the $9.6 million raised from the private placement to further its Antibody Drug Conjugate (ADC) and Radiopharmaceutical programs in Montreal, Quebec?
Given the recent investment in Defence Therapeutics Inc. Cl A DTCFF, what are the anticipated developments in the company's precision drug delivery platform in the next months?
What partnerships is Defence Therapeutics Inc. considering to enhance its research and development efforts in Montreal, Quebec, following the closing of its private placement on March 6, 2026?
How does the equity blocker provision on the warrants issued in the private placement influence potential investor interest in Defence Therapeutics Inc. Cl A DTCFF's stock performance?
**MWN-AI FAQ is based on asking OpenAI questions about Defence Therapeutics Inc Cl A (OTC: DTCFF).
NASDAQ: DTCFF
DTCFF Trading
0.0% G/L:
$0.4621 Last:
2,501 Volume:
$0.4621 Open:
